<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724890</url>
  </required_header>
  <id_info>
    <org_study_id>MS201964_0001</org_study_id>
    <nct_id>NCT03724890</nct_id>
  </id_info>
  <brief_title>Study of Avelumab-M3814 Combinations</brief_title>
  <official_title>A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose
      (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with
      avelumab with and without radiotherapy in participants with selected advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">October 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Occurrence of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>From first study intervention to planned final assessment at 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Occurrence of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>From first study intervention to planned final assessment at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part FE: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814</measure>
    <time_frame>Pre-dose up to end of treatment at 268 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part FE: Maximum Observed Drug Concentration (Cmax) of M3814</measure>
    <time_frame>Pre-dose up to end of treatment at 268 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Occurrence of Treatment-emergent Adverse Events (TEAEs) and Treatment-related AEs According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and Serious Adverse Events</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters, Vital Signs, Physical Examination, Electrocardiogram (ECG) Findings</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
    <description>Number of participants with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Status Assessed on Eastern Cooperative Oncology Group Performance Status (ECOG PS)</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Maximum Observed Drug Concentration (Cmax) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Minimum Observed Drug Concentration (Cmin) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation Ratio for Cmax [Racc(Cmax)] of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation Ratio for AUC [Racc (AUC)] of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Terminal Half-life (t1/2) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Maximum Observed Drug Concentration (Cmax) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Time to Reach the Maximum Plasma Concentration (tmax) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Minimum Observed Drug Concentration (Cmin) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Average Plasma Concentration of M3814 Observed Post-dose (Cavg)</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Fluctuation Index of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation ratio for Cmax [Racc(Cmax)] of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Accumulation ratio for AUC [Racc(Auc)] of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent Terminal Half-life (t1/2) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Clearance (CL/f) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Terminal Elimination Rate Constant (λz) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Positive Antidrug Antibody (ADA) Assay</measure>
    <time_frame>Part A and FE: From the first study intervention to planned final assessment at 299 days; Part B: From the first study intervention to planned final Part B assessment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Best Overall Response (BOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1)</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Duration of Response (DOR) as Assessed by the Investigators According to RECIST v 1.1</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Progression-free Survival (PFS) Time According to RECIST v 1.1 Assessed by Investigator</measure>
    <time_frame>Part A and FE: From baseline to planned final assessment at 305 days; Part B: From baseline to planned final assessment at 473 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Tumor size Based on Investigator Assessment According to RECIST v 1.1</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Overall Survival</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants with Radiotherapy (RT)-induced Toxicity According to NCI-CTCAE v 5.0</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Oncology</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M3814</intervention_name>
    <description>Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.</description>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
    <other_name>Peposertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M3814</intervention_name>
    <description>Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.</description>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <other_name>Peposertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.</description>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.</description>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A and Part FE (M3814 + avelumab): Participants must have histologically or
             cytologically proven advanced or metastatic solid tumors for which no standard therapy
             exists, standard therapy has failed, or participants are intolerant to or have
             rejected established therapy known to provide clinical benefit for their condition

          -  Part B (M3814 + Radiotherapy [RT] + avelumab): histologically or cytologically proven
             advanced or metastatic solid tumors for which no standard therapy exists, standard
             therapy has failed, or participants are intolerant to or have rejected established
             therapy known to provide benefit for their condition and are amenable to receive RT

          -  Part A, B and FE: Measurable or evaluable disease according to Response Evaluation
             Criteria in Solid Tumors Version 1.1 (RECIST v 1.1)

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at study
             entry

          -  Part A, B and FE: Female participants of childbearing potential should be willing to
             use a highly effective contraceptive method

          -  Part A, B and FE: Male participants should agree to refrain from donating sperm plus,
             either: abstain from any activity that allows for exposure to ejaculate

          -  Use an adequate method of contraception starting with the first dose of study therapy
             through 90 days after the last dose of study therapy

          -  Part A, B and FE: Be willing to provide informed consent for the trial

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants who have received prior chemotherapy, hormonal anticancer therapy with
             the exception of luteinizing hormone-releasing hormone analogs, biologic therapy, or
             any other anticancer therapy within 28 days of the first dose of study treatments (6
             weeks for nitrosoureas or mitomycin C)

          -  Participants who have undergone major surgery for any reason, except diagnostic
             biopsy, within 4 weeks of the study intervention and/or has not fully recovered from
             the surgery within 4 weeks of the study intervention

          -  Participants with evidence of active or history of autoimmune disease that might
             deteriorate when receiving an immune-stimulatory agent

          -  Participants with brain metastases, except those meeting the following criteria: a)
             brain metastases that have been treated locally and are clinically stable for greater
             than or equal to (&gt;=) 4 weeks prior to randomization b) no ongoing neurological
             symptoms that are related to the brain localization of the disease (sequelae that are
             a consequence of the treatment of the brain metastases are acceptable) c) participants
             must be either off steroids or on a stable or decreasing dose of less than (&lt;) 10
             milligrams (mg) daily prednisone (or equivalent)

          -  Participants with severe acute or chronic medical conditions including immune colitis,
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric
             conditions including recent (within the past year), psychiatric or substance abuse
             disorders; or active suicidal ideation or behavior; or laboratory abnormalities that
             may increase the risk associated with study participation or study intervention
             administration or may interfere with the interpretation of study results

          -  Participants requiring systemic immunosuppressive agents (such as steroids) for any
             reason who cannot be tapered off these drugs before start of study intervention, with
             the following exceptions: a) participants with adrenal insufficiency, may continue
             corticosteroids at physiologic replacement dose, equivalent to less than or equal to
             (&lt;=) 10 mg prednisone daily b) participants requiring steroids through a route known
             to result in a minimal systemic exposure (topical, intranasal, intra-ocular, or
             inhalation) is permitted c) participants with previous or ongoing administration of
             systemic steroids for the management of an acute allergic phenomenon planned to be
             completed in 14 days, or that the dose after 14 days will be equivalent to &lt;= 10 mg
             prednisone daily

          -  Participants with a history of human immunodeficiency virus (HIV) or known acquired
             immunodeficiency syndrome, Hepatitis B virus or Hepatitis C and with history of
             infection must have a polymerase chain reaction (PCR) documentation that infection is
             cleared

          -  Participants who have received a live vaccine within 30 days prior to the first dose
             of trial treatment

          -  Participants with known prior severe hypersensitivity to any of the investigational
             products or any component in its formulations

          -  Participants with evidence of additional malignancy within the last 5 years unless a
             complete remission without further recurrence was achieved at least 2 years prior to
             study entry and participants were deemed to have been cured with no additional therapy
             required or anticipated to be required. Participants with treated nonmelanoma skin
             cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate
             may participate

          -  Participants pretreated with immunotherapy who have, any history of dose limiting
             toxicities (DLTs) with prior immunotherapy agents, including Grade 3/4 immune-related
             adverse events (irAEs); irreversible irAEs; Grade greater than or equals to (&gt;=) 3
             irAEs that did not respond to steroid rescue; or neurologic irAE with significant
             clinical sequelae

          -  Participants with irAE requiring hormone replacement therapy (e.g., thyroxine,
             insulin, or physiologic dose of corticosteroid replacement therapy for adrenal or
             pituitary insufficiency) may participate as long as the endocrinopathy is well
             controlled and the participant is not otherwise symptomatic from hormone insufficiency

          -  Physiologic corticosteroid dose is defined as &lt;= 10 mg daily of prednisone or
             equivalent

          -  for Part B only:

          -  Participants who have confirmed esophagitis and in whom radiation planning target
             volume will include any portion of the esophagus, the participant is not eligible
             unless an esophageal endoscopy rules out the presence of esophagitis

          -  Participants in whom more than 10 percent (%) of the total esophagus volume might
             receive more than 15 gray (Gy) (50% of the prescribed radiotherapy [RT] dose)

          -  Participants who have had previous radiotherapy to the same region as intended to be
             irradiated in this study within the past 12 months

          -  Participants who have had extensive previous radiotherapy on &gt;= 30% of bone marrow
             reserve or prior bone marrow/stem cell transplantation within 5 years before study
             start

          -  If participant hepatic metastatic lesion is selected to be irradiated: - the non-tumor
             liver volume &lt; 700 milli liters (mL); - Child-Pugh score &gt;= 8

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72</phone>
    <phone_ext>5200</phone_ext>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc. - Pharmatech Oncology, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>peisenberg@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Peter D Eisenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - PRIME (10707)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Health Clinical Trials Office (10702)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>morri2j7@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>John C Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jluke@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Jason J Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>william.edenfield@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>William J Edenfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center (8867)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wade.iams@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Wade Iams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS201964_0001</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palliative Radiotherapy</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>M3814</keyword>
  <keyword>Avelumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

